Phyllanthus niruri L. is widely marketed as “stone breaker,” but it should not be treated as an exact botanical synonym for the Ayurvedic drug Bhūmyāmalakī. The Ayurvedic Pharmacopoeia of India (API) identifies Tāmalakī as the root, stem, and leaf of Phyllanthus fraternus G.L.Webster, recording P. niruri Hook.f. non L. as an older synonym. Clinical papers have examined several related species, especially P. niruri and P. amarus, whose findings should not be combined as though every preparation were identical.

Botanical Identity and Ayurvedic Recognition

The API describes Tāmalakī as an annual herb about 20–60 cm high and lists Mahidhātrikā, Bhūmyāmalakī, and Bahuphalā among its Sanskrit synonyms. Its slender branches bear small oblong leaves in two rows. Kew recognizes true P. niruri L. as native to tropical and subtropical America, whereas P. fraternus is a distinct species native from Pakistan to western India. Material sold as “Bhumi amla,” “Tāmalakī,” or “P. niruri” may therefore represent different small-leaved Phyllanthus species.

Ayurvedic Properties and Indications

For API-standard Tāmalakī, the recorded rasa are madhura, tikta, and kaṣāya—sweet, bitter, and astringent. Its guṇa are laghu and rūkṣa (light and dry), its vīrya is śīta (cooling), and its vipāka is madhura (sweet post-digestive effect). The API assigns mūtrala (urine-promoting), rocana (appetite-promoting), dāhanāśanī (relieving burning), and pittaśāmaka (pacifying pitta) actions. Listed therapeutic uses include amlapitta, kāsa, kṣaya, kuṣṭha, pāṇḍu, prameha, tṛṣā, kṣata, and mūtraroga. These traditional categories should not be converted automatically into modern diagnoses or promises of cure.

Phytochemical Profile

The API names phyllanthin as an important constituent of Tāmalakī. Genus-wide analyses report lignans, tannins, flavonoids, phenolics, terpenoids, and alkaloids, but the profile changes with species, plant part, geography, and extraction. Phyllanthin and hypophyllanthin are common analytical markers; their presence does not make two preparations clinically interchangeable or prove that one constituent produces the whole therapeutic effect.

Liver and Hepatoprotective Context

Several Phyllanthus extracts have produced antioxidant and hepatoprotective signals in experimental models. Human results are more restrained. In a 2021 double-blind, placebo-controlled trial in mild-to-moderate alcoholic hepatitis, 100 participants were recruited and 71 were included in the modified intention-to-treat analysis. Four weeks of P. niruri did not significantly improve the measured liver or renal function parameters, although total antioxidant levels and appetite-related assessment improved relative to placebo. It is better described as an investigated supportive botanical than an established liver treatment.

Antiviral Activity and the Hepatitis B Record

The frequently cited 1988 Lancet report concerned Phyllanthus amarus, not authenticated P. niruri L. After 30 days, HBsAg was no longer detected at the stated follow-up in 22 of 37 treated chronic carriers, compared with 1 of 23 given placebo. This preliminary result generated interest but did not establish the genus as antiviral therapy.

A later 12-month double-blind trial of P. niruri enrolled 50 people with chronic hepatitis B; 47 completed all visits. It found no significant difference from placebo in viral load, and no participant achieved HBsAg clearance. A Cochrane review judged the randomized evidence too biased and heterogeneous to establish convincing placebo-controlled benefit. Laboratory work on HBV replication remains preclinical. People with chronic hepatitis B should continue clinician-directed monitoring and indicated antiviral treatment; the World Health Organization lists oral medicines such as tenofovir or entecavir for chronic HBV care.

Kidney Stones and Urinary Use

Urinary use has an Ayurvedic basis—the API lists mūtrala action and mūtraroga—and an experimental literature. In laboratory and animal systems, P. niruri preparations have altered calcium oxalate crystal growth or aggregation. Human trials do not justify the literal claim that the herb “breaks” established stones.

In a 2004 randomized placebo-controlled study, 69 calcium-stone formers received a freeze-dried aqueous extract, 450 mg three times daily, or placebo for three months. Overall urinary measures, stone passage, and pain did not differ significantly between groups; a subgroup with hypercalciuria showed lower urinary calcium. In a 2018 prospective study without a parallel control group, 56 adults with stones smaller than 10 mm used a P. niruri infusion for 12 weeks. The mean number of stones decreased, while urinary oxalate and uric acid fell in the relevant high-excretion subgroups. A 2020 systematic review characterized the clinical evidence as limited and compatible with modest benefit, pending stronger controlled trials.

Clinical Evidence at a Glance

The table separates species, design, and outcome so that early positive findings are not blended with later neutral trials.

Indication Species and design Participants Duration Verified outcome
Chronic HBV carriage P. amarus, preliminary controlled trial; PMID 2901611 60 30 days HBsAg loss reported in 22/37 treated versus 1/23 placebo
Chronic hepatitis B P. niruri, double-blind placebo-controlled trial; PMID 30372693 50 enrolled; 47 completed 12 months No significant viral-load benefit and no HBsAg clearance
Calcium stone formation P. niruri, randomized placebo-controlled study; PMID 15221244 69 3 months No overall difference in passage or pain; urinary calcium fell in the hypercalciuric subgroup
Kidney stones under 10 mm P. niruri infusion, prospective uncontrolled study; PMID 29617079 56 12 weeks Fewer stones per patient and subgroup-specific urinary changes
Alcoholic hepatitis P. niruri, double-blind placebo-controlled trial; PMID 34975132 100 recruited; 71 analyzed 4 weeks No significant liver- or renal-function improvement; antioxidant and appetite signals

Traditional and Investigational Profile

The most defensible summary distinguishes pharmacopoeial tradition from laboratory hypotheses and clinical outcomes.

TĀMALAKĪ AND THE PHYLLANTHUS EVIDENCE BASE
AYURVEDIC PROFILE
Cooling, light, dry; mūtrala and pitta-pacifying actions in the API monograph

LIVER AND HBV
Preclinical activity and mixed human findings; not a replacement for antiviral or liver care

URINARY STONES
Possible effects on crystallization and selected urinary factors; clinical benefit remains modest

Safety, Quality, and Use

The cited controlled studies identified no serious treatment-related adverse events, but their size and duration do not establish unrestricted long-term safety. Species substitution, extraction strength, and contamination can change a product. Anyone with active hepatitis B, significant liver or kidney disease, recurrent stones, pregnancy or breastfeeding, or regular prescription medicines should consult both a qualified Ayurvedic practitioner and an appropriate healthcare provider before use. Herbal treatment must not delay diagnostic imaging, laboratory monitoring, or prescribed antiviral and urological care.

Dosage and Preparation

The API adult guidance for Tāmalakī is 10–20 mL in juice form or 3–6 g in powder form. These quantities refer to the authenticated API drug, not every capsule or concentrated extract. The 2004 kidney-stone trial used 450 mg of a freeze-dried aqueous extract three times daily, while other trials used different preparations. Dose selection should therefore follow authenticated sourcing, formulation strength, clinical context, and professional supervision rather than borrowing a dose from an unrelated study.

Conclusion

Bhūmyāmalakī/Tāmalakī is a legitimate Ayurvedic drug with clearly recorded properties, urinary indications, and pharmacopoeial doses, but its botanical identity must be kept separate from true Phyllanthus niruri L. and from P. amarus. Without species conflation, the modern record shows substantial laboratory findings, limited or subgroup-specific kidney-stone effects, and no definitive treatment role in controlled hepatitis B or liver trials. Authenticated material and coordinated professional care are essential.

References

  1. Ayurvedic Pharmacopoeia of India
  2. Powo (powo.science.kew.org)
  3. Powo (powo.science.kew.org)
  4. Phytochemicals from Phyllanthus niruri Linn. and their pharmacological properties: a review (2006), PubMed
  5. Efficacy of Phyllanthus niruri on improving liver functions in patients with alcoholic hepatitis: A double-blind randomized controlled trial (2021), PubMed
  6. Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus (1988), PubMed
  7. Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial (2018), PubMed
  8. Cochrane (cochrane.org)
  9. World Health Organization
  10. Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients (2004), PubMed
  11. Effect of phyllanthus niruri on metabolic parameters of patients with kidney stone: a perspective for disease prevention (2018), PubMed
  12. Phyllanthus niruri (stone breaker) herbal therapy for kidney stones; a systematic review and meta-analysis of clinical efficacy, and Google Trends analysis of public interest (2020), PubMed
  13. Scielo (scielo.br)
  14. Karger (karger.com)

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.